Free Trial

CONMED (CNMD) Earnings Date, Estimates & Call Transcripts

CONMED logo
$69.18 +0.55 (+0.80%)
(As of 12/23/2024 05:26 PM ET)

CONMED Latest Earnings Summary

Actual EPS
(Oct. 30)
$1.05 Beat By $0.06
Consensus EPS
(Oct. 30)
$0.99

CONMED announced Q3 2024 earnings on October 30, 2024, reporting an EPS of $1.05, which topped analysts' consensus estimates of $0.99 by $0.06. Quarterly revenue was reported to be $316.70 million, below the consensus estimate of $318.46 million. With a trailing EPS of $4.21 and a P/E Ratio of 16.43, CONMED's earnings are expected to grow 19.60% next year, from $4.03 to $4.82 per share.

Get CONMED Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CONMED and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

CNMD Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CNMD Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

CONMED Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20241$0.89$0.89$0.89 
Q2 20241$1.07$1.07$1.07 
Q3 20241$1.10$1.10$1.100.980 - 1.000
Q4 20241$1.28$1.28$1.28 
FY 20244$4.34$4.34$4.34 
Q1 20251$1.26$1.26$1.26 
Q2 20251$1.28$1.28$1.28 
Q3 20251$1.46$1.46$1.46 

CONMED Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
10/30/2024Q3 2024$0.99$1.05+$0.06$0.53$318.46M$316.70M
7/31/2024Q2 2024$0.92$0.98+$0.06$1.00$334.39M$332.10M
4/24/2024Q1 2024$0.74$0.79+$0.05$0.95$307.06M$312.27M
1/31/2024Q4 2023$1.11$1.06 -$0.05$1.07$332.94M$327.05M
10/25/2023Q3 2023$0.83$0.90+$0.07$1.30$301.22M$304.58M
7/26/2023Q2 2023$0.79$0.83+$0.04$1.23$306.15M$317.70M
4/26/2023Q1 2023$0.60$0.66+$0.06$1.26$266.66M$295.47M
2/2/2023Q4 2022$0.93$0.42 -$0.51-$0.02$302.48M$250.87M

CONMED Earnings - Frequently Asked Questions

CONMED (NYSE:CNMD) last announced its quarterly earning data on Wednesday, October 30, 2024. Learn more on CNMD's earnings history.

CONMED updated its FY 2024 earnings guidance on Wednesday, October, 30th. The company provided earnings per share (EPS) guidance of 4.000-4.050 for the period, compared to the consensus earnings per share estimate of 3.990. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.

In the previous quarter, CONMED (NYSE:CNMD) reported $1.05 earnings per share (EPS) to beat the analysts' consensus estimate of $0.99 by $0.06. Learn more on analysts' earnings estimate vs. CNMD's actual earnings.

The conference call for CONMED's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for CONMED's latest earnings report can be read online.
Read Transcript

CONMED's earnings report can be found in their filing with the SEC.
View SEC filing

CONMED (NYSE:CNMD) has a recorded annual revenue of $1.29 billion.

CONMED (NYSE:CNMD) has a recorded net income of $64.46 million. CNMD has generated $4.21 earnings per share over the last four quarters.

CONMED (NYSE:CNMD) has a trailing price-to-earnings ratio of 16.43 and a forward price-to-earnings ratio of 17.17. The price/earnings-to-growth ratio is 0.94.

CONMED's earnings are expected to grow from $4.03 per share to $4.82 per share in the next year, which is a 19.60% increase.

More Earnings Resources from MarketBeat



This page (NYSE:CNMD) was last updated on 12/24/2024 by MarketBeat.com Staff
From Our Partners